Table 1

Baseline characteristics of all patients initiating with csDMARD therapy and the subset of patients tapering DMARDs (synthetic and/or biological)

All patients (n=281)Tapering DMARDs (n=141)
Demographic
 Age, mean (SD)53 (14)52 (15)
 Sex, female, n (%)190 (68)79 (56)
Disease-related
 Duration of complaints, days, mean (SD)166 (91)168 (88)
 RF-positive, n (%)228 (81)17 (83)
 ACPA-positive, n (%)226 (80)108 (77)
 Fulfilling ACR/EULAR 1987 criteria, n (%)189 (67)96 (68)
 Fulfilling ACR/EULAR 2010 criteria, n (%)267 (95)134 (95)
 DAS, mean (SD)3.36 (0.96)3.18 (1.03)
 SJC44, median (IQR)7 (4–12)8 (4–12)
 ESR, median (IQR)24 (14–42)22 (12–39)
 CRP, median (IQR)9 (4–23)10 (5–26)
 TJC44, median (IQR)9 (4–14)7 (3–13)
 Global health, median (IQR)53 (33–69)50 (28–67)
 HAQ, mean (SD)1.00 (0.66)0.89 (0.62)
 tSvHs, median (IQR)0 (0–0)0 (0–0)
Complete follow-up at 2 years, n (%)248 (88)133 (94)
  • ACPA, anti-citrullinated protein antibody; ACR, American College of Rheumatology; CRP, C-reactive protein; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate; EULAR, European League Against Rheumatism; HAQ, Health Assessment Questionnaire; RF, rheumatoid factor; SJC44, 44 Swollen Joint Count; TJC44, 44 Tender Joint Count; tSvHs, total Sharp—van der Heijde Score.